DTIL

Precision Biosciences Inc

6.64

Oct 23 • 3:59 PM ET -0.14 (-2.06%)

6.71

Aftermarket • 7:56 PM ET +0.07 (1.05%)

Healthcare Biotechnology USA Micro NASD

Peers: EDIT PRME ABUS NTLA SCTX BEAM CRBU ALGS SLDB VIR

| Held by: VTI IWM VXF IWN VTWO FESM IWC AVSC GSSC DFAS

Scroll to Statements

Index	RUT
Market Cap	183.27M
Enterprise Value	123.82M
Income	-53.62M
Sales	45.05M
Book/sh	1.71
Cash/sh	3.17
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	68
IPO	Mar 28, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	4.07
P/B	3.88
P/C	2.09
P/FCF	-
EV/EBITDA	-
EV/Sales	2.75
Quick Ratio	12.82
Current Ratio	12.82
Debt/Eq	0.62
LT Debt/Eq	0.58
Option/Short	Yes / Yes

EPS (ttm)	-2.85
EPS next Y	-2.84
EPS next Q	-0.85
EPS this Y	-0.96%
EPS next Y	20.98%
EPS next 5Y	17.58%
EPS past 3/5Y	54.31% 43.45%
Sales past 3/5Y	10.93% 7.13%
EPS Y/Y TTM	67.74%
Sales Y/Y TTM	3472.96%
EPS Q/Q	40.69%
Sales Q/Q	-100.00%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-56.72% -100.00%

Insider Own	13.49%
Insider Trans	0.13%
Inst Own	66.66%
Inst Trans	8.66%
ROA	-45.66%
ROE	-135.15%
ROIC	-74.69%
Gross Margin	94.24%
Oper. Margin	-80.78%
Profit Margin	-119.00%
SMA20	4.81%
SMA50	-5.19%
SMA200	2.73%
Trades

Shs Outstand	26.43M
Shs Float	23.88M
Short Float	10.53%
Short Ratio	9.70
Short Interest	2.51M
52W High	9.62 -30.98%
52W Low	3.53 88.10%
Volatility	6.84% 5.84%
ATR (14)	0.39
RSI (14)	52.04
Beta	1.37
Rel Volume	1.06
Avg Volume	259.18K
Volume	275,536

Perf Week	15.08%
Perf Month	4.90%
Perf Quarter	-8.41%
Perf Half Y	-5.68%
Perf YTD	59.62%
Perf Year	-4.18%
Perf 3Y	-25.53%
Perf 5Y	-97.71%
Perf 10Y	-
Recom	1.00
Target Price	29.40
Prev Close	6.78
Price	6.64
Change %	-2.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-26	Initiated	Oppenheimer	Outperform	$20
Jan-10-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$34
Apr-30-24	Initiated	Guggenheim	Buy	$19
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$7
Jun-09-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-27-20	Resumed	BTIG Research	Buy	$16
Apr-03-20	Downgrade	Goldman	Buy → Neutral	$24 → $7
Mar-05-20	Initiated	Stifel	Buy	$21
Feb-25-20	Initiated	William Blair	Outperform
Aug-09-19	Initiated	BTIG Research	Buy	$22
Jul-16-19	Initiated	H.C. Wainwright	Buy	$21
Apr-22-19	Initiated	JP Morgan	Overweight
Apr-22-19	Initiated	Jefferies	Buy
Apr-22-19	Initiated	Goldman	Buy
Apr-22-19	Initiated	Barclays	Overweight

Show Previous Ratings

Oct-08-26 07:01AM	Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 (Business Wire)
Aug-24-26 06:01AM	Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study (Business Wire)
Aug-06-26 07:24AM	Precision BioSciences: Q2 Earnings Snapshot (Associated Press)
07:01AM	Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Jul-31-26 07:01AM	Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
07:01AM	Loading…
Jul-27-26 07:01AM	Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones (Business Wire)
Jul-10-26 07:01AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-29-26 07:01AM	Precision BioSciences Announces Inclusion in the Russell 2000 Index Expanding Market Visibility with Institutional Investors (Business Wire) +8.64%
May-27-26 02:30AM	Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026 (Business Wire)
May-21-26 07:01AM	Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026 (Business Wire)
May-14-26 07:01AM	Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting (Business Wire)
May-05-26 07:09AM	Precision BioSciences: Q1 Earnings Snapshot (Associated Press)
07:01AM	Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Apr-30-26 07:01AM	Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 (Business Wire)
Apr-29-26 07:01AM	Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study (Business Wire)
07:01AM	Loading…
Apr-28-26 07:01AM	Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting (Business Wire)
Apr-24-26 07:01AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-22-26 07:01AM	Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 (Business Wire) +6.32%
Apr-15-26 07:01AM	Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries (Business Wire) +5.95%
Apr-08-26 07:01AM	Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-12-26 07:15AM	Precision BioSciences: Q4 Earnings Snapshot (Associated Press Finance) +12.06%
07:00AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update (Business Wire)
Mar-11-26 07:01AM	Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program (Business Wire) -5.42%
Mar-10-26 07:01AM	Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 (Business Wire) +13.59%
Mar-09-26 05:35PM	Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 (Business Wire)
07:01AM	Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event (Business Wire)
Mar-02-26 07:01AM	Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis (Business Wire)
Feb-26-26 06:00PM	Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +5.26%
Feb-23-26 10:35AM	Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:01AM	Loading…
Feb-18-26 07:01AM	Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
Jan-12-26 07:01AM	Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy (Business Wire)
Dec-23-25 07:00AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-19-25 07:01AM	Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 (Business Wire) -7.66%
Nov-10-25 06:12PM	Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants (Business Wire)
05:21PM	Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts (Business Wire)
Nov-03-25 07:10AM	Precision BioSciences: Q3 Earnings Snapshot (Associated Press Finance) -9.80%
07:01AM	Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Oct-31-25 07:01AM	Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025 (Business Wire) -5.23%
Oct-16-25 08:05AM	Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last? (Zacks)
Oct-14-25 07:01AM	Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2025 (Business Wire) +5.22%
Oct-09-25 07:01AM	Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases (Business Wire)
Oct-07-25 07:01AM	Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial (Business Wire)
Sep-30-25 07:01AM	Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society (Business Wire) +8.45%
Sep-25-25 06:30AM	Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? (Zacks)
Sep-12-25 07:01AM	Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium (Business Wire) -7.80%
Sep-08-25 07:01AM	Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status (Business Wire)
Aug-07-25 09:25AM	Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
08:24AM	Precision BioSciences: Q2 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Aug-06-25 05:45PM	Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:01AM	Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B (Business Wire)
Aug-05-25 06:20PM	Qiagen (QGEN) Matches Q2 Earnings Estimates (Zacks)
Aug-04-25 07:01AM	Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 (Business Wire)
Jul-23-25 07:01AM	Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (Business Wire)
Jul-16-25 07:01AM	Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic (Business Wire)
Jun-25-25 07:01AM	Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (Business Wire) -7.22%
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-15-25 08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.08%
07:11AM	Precision BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-14-25 05:45PM	Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:30PM	Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-12-25 05:30PM	Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:01AM	Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 (Business Wire)
May-07-25 07:01AM	Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) (Business Wire)
May-06-25 05:15PM	Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -9.09%
08:00AM	iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings (Business Wire)
May-05-25 04:44AM	CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts (Seeking Alpha)
May-01-25 07:01AM	Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
Apr-29-25 07:00AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-16-25 08:52AM	DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up (Zacks) -9.24%
Apr-15-25 07:01AM	Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B (Business Wire) +23.77%
Apr-10-25 11:50AM	TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why (Zacks) -7.03%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -5.87%
07:01AM	Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-26-25 08:10AM	Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -11.00%
07:09AM	Precision BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update (Business Wire)
Mar-21-25 07:01AM	Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 (Business Wire)
Mar-20-25 07:01AM	Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 (Business Wire) +6.99%
Mar-19-25 06:25PM	Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:01AM	Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Mar-17-25 07:01AM	Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B (Business Wire)
Feb-24-25 07:01AM	Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire) -5.06%
Feb-20-25 07:47AM	Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV (Clinical Trials Arena)
Feb-19-25 02:27PM	Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate (Benzinga) +9.71%
07:01AM	Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial (Business Wire)
Jan-29-25 07:01AM	Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs (Business Wire)
Jan-09-25 10:01AM	Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
08:00AM	iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
Dec-19-24 05:42AM	Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial (Clinical Trials Arena) +11.38%
Dec-18-24 07:01AM	Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B (Business Wire) -9.83%
Nov-21-24 07:01AM	Precision BioSciences to Participate in Upcoming November Investor Conferences (Business Wire) -9.47%
Nov-15-24 07:00AM	Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B (Business Wire)
Nov-04-24 08:15AM	Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -8.09%
07:13AM	Precision BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-01-24 07:43AM	Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? (Zacks) +5.37%
Oct-29-24 07:01AM	Precision BioSciences to Report Third Quarter Results on November 4, 2024 (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Frankel Stanley	Director	Sep 28 '26	Buy	6.00	1,000	6,000	41,478	Sep 30 04:15 PM
Brown Melinda	Director	Sep 25 '26	Buy	6.27	1,135	7,116	45,481	Sep 29 07:00 AM
Germano Geno J	Director	Sep 25 '26	Buy	6.28	2,609	16,385	47,492	Sep 29 07:00 AM
Amoroso Michael	President and CEO	Feb 17 '26	Option Exercise	0.00	67,797	0	263,951	Feb 19 04:31 PM
Amoroso Michael	President and CEO	Feb 18 '26	Sale	3.84	20,559	78,947	243,392	Feb 19 04:31 PM
Kelly John Alexander	Chief Financial Officer	Feb 17 '26	Option Exercise	0.00	27,584	0	134,032	Feb 19 04:31 PM
Kelly John Alexander	Chief Financial Officer	Feb 18 '26	Sale	3.84	8,149	31,292	125,883	Feb 19 04:31 PM
Scimeca Dario	General Counsel and Secretary	Feb 17 '26	Option Exercise	0.00	16,667	0	61,382	Feb 19 04:30 PM
Scimeca Dario	General Counsel and Secretary	Feb 18 '26	Sale	3.84	4,925	18,912	56,457	Feb 19 04:30 PM
SMITH J. JEFFERSON	Chief Research Officer	Feb 17 '26	Option Exercise	0.00	16,667	0	126,851	Feb 19 04:30 PM
SMITH J. JEFFERSON	Chief Research Officer	Feb 18 '26	Sale	3.84	4,925	18,912	121,926	Feb 19 04:30 PM
SMITH J. JEFFERSON	Officer	Feb 18 '26	Proposed Sale	3.84	4,925	18,929		Feb 18 05:05 PM
Scimeca Dario	Officer	Feb 18 '26	Proposed Sale	3.84	4,925	18,929		Feb 18 04:31 PM
Amoroso Michael	Officer	Feb 18 '26	Proposed Sale	3.84	20,559	79,019		Feb 18 04:30 PM
Kelly John Alexander	Officer	Feb 18 '26	Proposed Sale	3.84	8,149	31,321		Feb 18 04:19 PM
Amoroso Michael	President and CEO	Jan 22 '26	Sale	4.17	34,799	145,112	196,154	Jan 22 06:49 PM
Scimeca Dario	General Counsel and Secretary	Jan 20 '26	Option Exercise	0.00	25,311	0	53,569	Jan 22 06:48 PM
Scimeca Dario	General Counsel and Secretary	Jan 21 '26	Sale	4.03	8,854	35,682	44,715	Jan 22 06:48 PM
Kelly John Alexander	Chief Financial Officer	Jan 21 '26	Sale	4.03	15,213	61,308	106,448	Jan 22 06:48 PM
SMITH J. JEFFERSON	Chief Research Officer	Jan 21 '26	Sale	4.03	10,200	41,106	110,184	Jan 22 06:48 PM
Amoroso Michael	Officer	Jan 22 '26	Proposed Sale	4.17	34,799	145,202		Jan 22 03:19 PM
Scimeca Dario	Officer	Jan 21 '26	Proposed Sale	4.03	8,854	35,653		Jan 21 04:19 PM
SMITH J. JEFFERSON	Officer	Jan 21 '26	Proposed Sale	4.03	10,200	41,073		Jan 21 04:14 PM
Kelly John Alexander	Officer	Jan 21 '26	Proposed Sale	4.03	15,213	61,260		Jan 21 04:07 PM
Germano Geno J	Director	Dec 16 '25	Buy	4.72	3,000	14,160	23,883	Dec 17 07:02 AM
Frankel Stanley	Director	Dec 16 '25	Buy	4.70	2,700	12,690	19,478	Dec 17 07:01 AM
Brown Melinda	Director	Dec 15 '25	Buy	4.97	1,381	6,864	23,346	Dec 17 07:00 AM
Kelly John Alexander	Chief Financial Officer	Nov 02 '25	Option Exercise	0.00	3,605	0	78,601	Nov 04 04:15 PM
Kelly John Alexander	Chief Financial Officer	Nov 03 '25	Sale	6.49	1,303	8,456	77,298	Nov 04 04:15 PM
Scimeca Dario	General Counsel and Secretary	Nov 02 '25	Option Exercise	0.00	1,835	0	28,923	Nov 04 04:15 PM
Scimeca Dario	General Counsel and Secretary	Nov 03 '25	Sale	6.49	665	4,316	28,258	Nov 04 04:15 PM
Amoroso Michael	President and CEO	Nov 02 '25	Option Exercise	0.00	9,444	0	118,984	Nov 04 04:15 PM
Amoroso Michael	President and CEO	Nov 03 '25	Sale	6.49	3,409	22,124	115,575	Nov 04 04:15 PM
Kelly John Alexander	Officer	Nov 03 '25	Proposed Sale	6.49	1,303	8,455		Nov 03 03:16 PM
Amoroso Michael	Officer	Nov 03 '25	Proposed Sale	6.49	3,409	22,121		Nov 03 03:15 PM
Scimeca Dario	Officer	Nov 03 '25	Proposed Sale	6.49	665	4,315		Nov 03 03:07 PM

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

PresidentMr. Michael Amoroso

Chief Operating OfficerMr. John Alexander Kelly R.Ph.

Chief Legal Officer & SecretaryMr. Dario Scimeca J.D.

Co-Founder & Chief Research OfficerDr. Jefferson J. Smith Ph.D.

Chief Financial OfficerMr. Naresh Tanna

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DTIL

Precision Biosciences Inc

Upgrade your Finviz experience